Migalastat HCl | GR181413A | α-galactosidase A Inhibitor

首页 / 抑制剂/激动剂 / 代谢酶 / Galactosidases / Migalastat HCl

Migalastat HCl {[allProObj[0].p_purity_real_show]}

货号：A312646 同义名： GR181413A;1-Deoxygalactonojirimycin (hydrochloride)

Migalastat hydrochloride is a potent and selective α-galactosidase inhibitor (α-Gal A) with IC50 of 0.04 μM.

Migalastat HCl 化学结构
CAS号：75172-81-5

Migalastat HCl 3D分子结构
CAS号：75172-81-5

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Migalastat HCl 纯度/质量文件产品仅供科研

货号：A312646 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Cell Host Microbe, 2024. Ambeed. [ A163338 ]; • Cancer Res., 2024. Ambeed. [ A295334 ]; • J. Pharm. Investig., 2024. Ambeed. [ A221527 , A691302 , A272538 , A187261 ]; • J. Fungi, 2024, 10(11): 751. Ambeed. [ A796919 ]; • JBC, 2024, 107935. Ambeed. [ A194396 ]; 更多 >

Migalastat HCl 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT03683966	-		Recruiting	March 31, 2019	Germany ... 展开 >> Wuerzburg University Hospital Recruiting Würzburg, Bayern, Germany, 97080 Contact: Irina Schumacher 004993120139714 schumacher_i@ukw.de 收起 <<
NCT01730482	Fabry Disease	Phase 1	Completed	-	-
NCT01218659	Fabry Disease	Phase 3	Completed	-	-

Migalastat HCl 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

5.01mL

1.00mL

0.50mL

25.05mL

5.01mL

2.50mL

50.09mL

10.02mL

5.01mL

Migalastat HCl 技术信息

CAS号	75172-81-5
分子式	C₆H₁₄ClNO₄
分子量	199.633

别名	GR181413A;1-Deoxygalactonojirimycin (hydrochloride);Migalastat;DGJ;Migalastat hydrochloride
运输	蓝冰

存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Inert atmosphere,Store in freezer, under -20°C

溶解度

H₂O: 200 mg/mL(1001.84 mM)

动物实验配方

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT03683966	-		Recruiting	March 31, 2019	Germany ... 展开 >> Wuerzburg University Hospital Recruiting Würzburg, Bayern, Germany, 97080 Contact: Irina Schumacher 004993120139714 schumacher_i@ukw.de 收起 <<
NCT01730482	Fabry Disease	Phase 1	Completed	-	-
NCT01218659	Fabry Disease	Phase 3	Completed	-	-
NCT01218659	-		Completed	-	-
NCT01489995	Fabry Disease	Phase 1	Completed	-	United States, Texas ... 展开 >> GSK Investigational Site Austin, Texas, United States, 78744 收起 <<
NCT00925301	-		Completed	-	-
NCT01730469	Fabry Disease	Phase 1	Completed	-	United States, California ... 展开 >> GSK Investigational Site Costa Mesa, California, United States, 92626 United States, Florida GSK Investigational Site Miami, Florida, United States, 33014 GSK Investigational Site Miami, Florida, United States, 33169 GSK Investigational Site Orlando, Florida, United States, 32809 收起 <<
NCT01196871	Fabry Disease	Phase 2	Completed	-	United States, Alabama ... 展开 >> Birmingham, Alabama, United States, 35294 United States, Georgia Decatur, Georgia, United States, 30033 United States, Iowa Iowa City, Iowa, United States, 52242 United States, Kansas Kansas City, Kansas, United States, 66160 United States, Virginia Springfield, Virginia, United States, 22152 Australia Nedlands, Australia Parkville, Australia Belgium Edegem, Belgium Canada Montreal, Canada Netherlands Amsterdam, Netherlands 收起 <<
NCT00283959	-		Completed	-	-
NCT01196871	-		Completed	-	-
NCT00283933	Fabry Disease	Phase 2	Completed	-	France ... 展开 >> Paris, France, 75015 United Kingdom London, United Kingdom, NW3 2QG 收起 <<
NCT01853852	Fabry Disease	Phase 1	Completed	-	Australia, New South Wales ... 展开 >> GSK Investigational Site Randwick, New South Wales, Australia, 2031 收起 <<
NCT00283933	-		Completed	-	-
NCT00304512	Fabry Disease	Phase 2	Completed	-	United States, Georgia ... 展开 >> Decatur, Georgia, United States, 30033 Australia, Victoria Parkville, Victoria, Australia, 3050 Brazil Porto Alegre, Brazil, RS, 90035-903 Canada Montréal, Canada, H4J 1C5 France Paris, France, 75015 United Kingdom Salford, United Kingdom, M6 8HD 收起 <<
NCT00304512	-		Completed	-	-
NCT01458119	Fabry Disease	Phase 3	Terminated(Amicus Therapeutics... 展开 >> discontinued Study AT1001-041 for logistical reasons.) 收起 <<	-	-
NCT00283959	Fabry Disease	Phase 2	Completed	-	Australia ... 展开 >> Parkville, Australia Brazil Porto Alegre, Brazil 收起 <<
NCT01458119	-		Terminated(Amicus Therapeutics... 展开 >> discontinued Study AT1001-041 for logistical reasons.) 收起 <<	-	-
NCT00526071	Fabry Disease	Phase 2	Terminated(The Sponsor (Amicus... 展开 >> Therapeutics) terminated this study for logistical reasons.) 收起 <<	-	United States, Georgia ... 展开 >> Decatur, Georgia, United States, 30033 United States, New York New York, New York, United States, 10016 United States, Texas Dallas, Texas, United States, 78226 Australia Parkville, Australia Brazil Porto Alegre, Brazil France Garches, France United Kingdom London, United Kingdom Salford, United Kingdom 收起 <<
NCT00214500	Fabry Disease	Phase 2	Completed	-	United States, California ... 展开 >> Los Angeles, California, United States, 90048 United States, Georgia Decatur, Georgia, United States, 30033 United States, Maryland Bethesda, Maryland, United States, 20892 United States, New York New York, New York, United States, 10016 United States, Texas Houston, Texas, United States, 77030 收起 <<
NCT03135197	-		Active, not recruiting	September 2019	Germany ... 展开 >> Universtiy Hospital Münster Münster, Germany, 48149 收起 <<
NCT00214500	-		Completed	-	-
NCT01476163	-		-	-	United States, California ... 展开 >> CHOC Children's Hospital Division of Metabolic Disease Orange, California, United States, 92868 Contact: Nina Movsesyan, PhD 714-509-3008 nmovsesyan@CHOC.org Principal Investigator: Raymond Y Wang, MD United States, Maryland University of Maryland Medical Center Baltimore, Maryland, United States, 21201 Contact: Elizabeth A Streeten, MD 410-706-6236 estreete@som.umaryland.edu United States, Massachusetts Kidney Care and Transplant Services of New England Springfield, Massachusetts, United States, 01104 Contact: Gregory L Braden, MD 413-733-0010 Gregory.Braden@baystatehealth.org Contact: Ann Vasseur (413) 733-0010 ext 143 ann@kidneycare-ne.com United States, New York Icahn School of Medicine at Mount Sinai New York, New York, United States, 10029 Contact: Manisha Balwani, MD 212-241-0915 manisha.balwani@mssm.edu Contact: Chanan Stauffer, MS, RN 212-241-0395 chanan.stauffer@mssm.edu Australia, Victoria Royal Melbourne Hospital Parkville, Victoria, Australia, 3050 Contact: Donna North +61 03 934 24219 donna.north@mh.org.au Principal Investigator: Kathleen Nicholls, MD 收起 <<
NCT02082327	Fabry Disease	Phase 1	Completed	-	Netherlands ... 展开 >> PRA International Groningen, Netherlands, 9713 GZ 收起 <<
NCT02194985	Fabry Disease	Phase 3	Active, not recruiting	October 2019	-
NCT03500094	Fabry Disease	Phase 3	Recruiting	September 1, 2020	United States, Florida ... 展开 >> University of South Florida Recruiting Tampa, Florida, United States, 33606 United States, Georgia Emory University Division of Medical Genetics Recruiting Decatur, Georgia, United States, 30033 United States, Missouri University of Missouri Recruiting Columbia, Missouri, United States, 65201 United States, Ohio Cincinnati Children's Hospital Not yet recruiting Cincinnati, Ohio, United States, 45229 United States, Pennsylvania Children's Hospital of Philadelphia Not yet recruiting Philadelphia, Pennsylvania, United States, 19104 Children's Hospital of Pittsburgh of UPMC Recruiting Pittsburgh, Pennsylvania, United States, 15224 United States, Virginia Lysosomal & Rare Disorders Research & Treatment Center Recruiting Fairfax, Virginia, United States, 22030 收起 <<
NCT00925301	Fabry Disease	Phase 3	Completed	-	-
NCT00526071	-		Terminated(The Sponsor (Amicus... 展开 >> Therapeutics) terminated this study for logistical reasons.) 收起 <<	-	-

Migalastat HCl {[allProObj[0].p_purity_real_show]}

Migalastat HCl 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Migalastat HCl 质控信息

Migalastat HCl 临床研究

Migalastat HCl 实验方案

Migalastat HCl 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Migalastat HCl {[allProObj[0].p_purity_real_show]}

Migalastat HCl 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Migalastat HCl 质控信息

Migalastat HCl 临床研究

Migalastat HCl 实验方案

Migalastat HCl 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Migalastat HCl 纯度/质量文件产品仅供科研